INSMInsmed Incorporated
128.13USD-1.94%Mkt Cap: 28.53B $P/E:

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory …

Key Statistics

Company
Market Cap28.53B $
Enterprise Value26.89B $
Revenue (TTM)1.14B $
Gross Profit483.49M $
Net Income (TTM)-1.28B $
Revenue/Share5.299 USD
Last Price128.13 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.7K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN
Valuation
P/E (Trailing)
P/E (Forward)173.75
PEG1.09
EV/EBITDA-33.83
EV/Revenue23.64
P/S24.01
P/B36.05
EPS (TTM)-3.94
EPS (Forward)0.72
52W Range
90.3931% of range212.75
52W High212.75 USD
52W Low90.39 USD
Profitability
Gross Margin79.73%
Oper. Margin-23.81%
EBITDA Margin-69.88%
Profit Margin-210.54%
ROE-172.78%
ROA-56.38%
Growth
Revenue Growth296.10%
Earnings Growth
Cash Flow & Leverage
Operating CF-935.01M $
CapEx (TTM)32.56M $
FCF Margin-50.26%
FCF Yield-2.00%
Net Debt-420.59M $
Net Debt/EBITDA0.53
Balance Sheet
Debt/Equity0.73
Current Ratio3.72
Quick Ratio3.13
Book Value/Sh3.470 USD
Cash/Share5.313 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Splits
Last Split1:10
Split DateMar 3, 2011
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)200.05 USD
Upside (mean)+56.1%
Target Range169.00 USD243.00 USD
$169.00+56.1% to mean$243.00
# Analysts22
Ownership
Shares Out.218.38M
Float216.86M
Insiders0.51%
Institutions104.83%
Short Interest
Short Ratio4.7d
Short % Float5.86%
Short % Out.5.20%
Shares Short11.35M
Short (prev mo.)16.03M
Technical
SMA 50110.12 (+16.3%)
SMA 200144.48 (-11.3%)
Beta0.79
S&P 52W Chg18.16%
Avg Vol (30d)2.83M
Avg Vol (10d)2.37M
Technical Indicators
RSI (14)65.3
MACD6.2700
MACD Signal4.5852
MACD Hist.+1.6848
BB Upper144.08 USD
BB Middle115.08 USD
BB Lower86.08 USD
BB Width50.40%
ATR (14)5.791 USD
Vol Ratio (20d)0.47x